Webdisclosure.com

Search

NICOX (EPA:COX) Nicox’s NCX 4251 Meets Primary Endpoint in Phase 2 Blepharitis Trial and Shows Promising Efficacy in Dry Eye Disease

Directive transparence : information réglementée

19/12/2019 07:30